Related Experiment Videos
Successful treatment with daclizumab of refractory anaplastic lymphoma
Vítor Costa1, Teresa Oliva, Lucília Norton
1Departamento de Pediatria, Instituto Português de Oncologia Francisco Gentil, Porto, Portugal. vitormendescosta@hotmail.com
Abstract:
Anaplastic large cell lymphoma (ALCL) is a relatively rare and highly malignant form of non-Hodgkin lymphoma (NHL) which accounts for 10-15% of these childhood lymphomas. Current treatment protocols for ALCL in children consist of a short course of high intensity polychemotherapy. Here we describe an 8-year-old female with relapsed ALCL who achieved good response with anti-CD25 monoclonal antibody daclizumab. Daclizumab appears to offer a safe treatment option, but further research needs to be conducted in order to define its role in children with ALCL who do not respond to intensive chemotherapy.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers